How AI Technologies Are Enhancing Oncology Research and Clinical Decisions

The study of cancer, known as oncology, has a long scientific history that began with early medical observations during the nineteenth century. Physicians and researchers worked to understand how abnormal cells grow and spread inside the human body. Early diagnosis depended mainly on physical examination, laboratory testing, and microscopic analysis of tissue samples. As medical science progressed, imaging technology and laboratory research improved the ability of doctors to identify different types of cancer and observe disease progression with greater clarity.

AI gradually entered the field of oncology as computing technology became more powerful. Machine learning algorithms were developed to study medical images, pathology slides, and genomic data. These systems can recognize patterns within large medical datasets and assist clinicians in identifying abnormal tissue structures, predicting disease behavior, and supporting treatment planning. AI tools are designed to support medical professionals by providing additional insights during diagnostic and therapeutic decisions.

Recent innovation focuses on deep learning models capable of analyzing radiology images, digital pathology data, and genetic information. These developments represent an important step in the evolution of oncology, where AI supports more precise diagnosis, personalized treatment strategies, and improved patient care in modern healthcare systems.

Fortune Business Insights reported that the market for AI in oncology achieved USD 3.66 billion in 2025 and is anticipated to reach USD 33.09 billion by 2034 with a significant CAGR of 28.58% over the estimated timeframe.

List of Top 10 AI in Oncology Companies Reported by Fortune Business Insights: 

1. Tempus

Tempus combines AI with extensive genomic sequencing to deliver personalized cancer treatment strategies through its xT platform. Headquartered in the U.S., the company processes tumor DNA profiles against millions of de-identified patient records generating ranked therapy recommendations matching individual molecular alterations precisely for oncologists treating diverse malignancies across community hospitals nationwide. Tempus enables precision medicine adoption systematically through evidence-based clinical decision support derived from comprehensive real-world oncology datasets continuously. In March 2026, the company announced a collaboration with Daiichi Sankyo to combine clinical trial and preclinical research data of the firm with Tempus’s exclusive real-world data.

2. Azra AI

Azra AI, headquartered in the U.S. streamlines prostate cancer diagnosis through deep learning analysis of digital pathology slides achieving expert-level Gleason pattern recognition alongside quantitative tumor burden assessment guiding urologists toward definitive treatment decisions confidently. The company prioritizes complex cases within high-volume laboratories accelerating turnaround times substantially. Moreover, its predictive algorithms highlight diagnostic uncertainty supporting quality assurance protocols throughout national screening programs serving millions of patients annually. In October 2025, the company collaborated with Reverain Technologies to adopt advanced AI for end-to-end lung cancer detection.

3. Ibex Medical Analytics

Ibex Medical Analytics powers prostate pathology with Galen AI platform analyzing biopsy specimens to predict Gleason scores and quantify cancer volume supporting active surveillance protocols for low-risk patients worldwide. Headquartered in Israel, Ibex reduces diagnostic variability through standardized reporting. It also streamlines workflows across community practices efficiently. This serves national screening initiatives with trials confirming substantial efficiency gains throughout healthcare networks internationally.

4. SOPHiA GENETICS

Sophia Genetics, headquartered in the U.S., facilitates global oncology research through federated AI learning within DDM platform matching patient genomic variants against massive reference datasets. It also derives clinical trial eligibility probabilities quantitatively across international cancer centers. The company preserves institutional data sovereignty. It also enables cross-border collaborations supporting immunotherapy response prediction through standardized variant interpretation. This allows diverse patient populations to systematically coordinate molecular tumor board consensus efficiently worldwide.

5. PathAI, Inc.

PathAI enhances breast cancer pathology precision through Halcyon platform measuring ER/PR/HER2 biomarker expression quantitatively alongside morphological assessment within routine slides producing standardized reports guiding therapy selection decisions across subtypes efficiently. Headquartered in the U.S., it continuously benchmarks individual pathologist performance against national quality standards while discordance prediction supports peer review throughout academic centers and community hospitals nationwide driving diagnostic consistency systematically improving patient outcomes consistently. In June 2025, the company received a FDA 510 (k) clearance for its AISight Dx platform for primary diagnosis in clinical settings.

6. Siemens Healthineers AG

Siemens Healthineers, headquartered in Germany, analyzes lung screening CTs through AI-Rad Companion quantifying nodule progression rates calibrated to Lung-RADS criteria while automating triage of actionable findings for multidisciplinary review across European networks efficiently. The company reduces radiologist reading times substantially through structured report generation. This supports population health screening initiatives with prospective validation confirming sensitivity improvements and lung cancer early detection systematically.

7. Insilico Medicine

Insilico Medicine accelerates cancer drug discovery through generative AI platforms targeting undruggable pathways designing novel inhibitors de novo with nanomolar potency predicting clinical success probabilities quantitatively throughout pharmaceutical partnerships worldwide. Headquartered in the U.S., Insilico employs reinforcement learning optimization streamlining preclinical development timelines substantially serving precision medicine innovation across global collaborations with rational structure generation enabling rapid candidate prioritization systematically across oncology portfolios efficiently. In February 2026, the company collaborated with Memorial Sloan Kettering Cancer Center (MSK) to identify the prime targets for gastroesophageal cancers.

8. Guardant Health, Inc.

Guardant Health Inc., headquartered in the U.S., transforms metastatic cancer management through Guardant360 blood-based profiling detecting actionable alterations noninvasively guiding therapy selection, while Reveal monitors residual disease predicting recurrence risk quantitatively post-treatment nationwide. The company analyzes methylation signatures determining cancer origin alongside comprehensive gene panels. This helps in immunotherapy decisions serving oncologists to track treatment response systematically.

9. Hoffmann-La Roche

Hoffmann-La Roche orchestrates molecular tumor boards through Navify platform matching genomic profiles against clinical trials while Digital Pathology AI quantifies PD-L1 expression predicting immunotherapy outcomes precisely across cancer centers internationally. Headquartered in Switzerland, it automates evidence synthesis supporting therapeutic consensus efficiently with spatial biomarker analysis enhancing diagnostic workflows. This helps in coordinating multidisciplinary expertise serving precision oncology implementation worldwide.

10. Elekta

Elekta automates radiotherapy contouring across prostate, brain, and lung cancers through AI segmentation achieving expert-level precision while accelerating VMAT planning workflows substantially throughout radiation oncology departments globally. Headquartered in Sweden, the company generates accurate treatment volumes supporting dosimetric optimization systematically. It also confirms planning equivalence, thus serving quality assurance programs and enhancing cancer treatment accuracy efficiently.

Advancements AI Technology Will Boost Adoption of AI in Oncology

Future oncology platforms would integrate digital systems that combine imaging data, genomic information, and patient health records within a unified analytical framework. These systems could support continuous monitoring of disease progression and treatment response. As scientific research and medical technology continue to evolve, AI will remain an important partner in oncology practice. Its development reflects a future guided by precision medicine, advanced data interpretation, and intelligent healthcare systems designed to improve patient outcomes and support modern cancer care.